Analysing the eosinophil cationic protein - a clue to the function of the eosinophil granulocyte

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Bystrom, Jonas ^a   Amin, Kawa ^b,c   Bishop Bailey, David ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF SULAIMANI   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN; BIOLOGICAL MARKER;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; BACTERIAL SINUSITIS; BLADDER TUMOR; BONE MARROW; BRONCHUS MUSCLE; DNA POLYMORPHISM; EOSINOPHIL; EPITHELIUM; GENE; HELMINTHIASIS; HOMEOSTASIS; HUMAN; HYPEREOSINOPHILIC SYNDROME; INFLAMMATION; INFLAMMATORY DISEASE; KAPOSI SARCOMA; LYMPHOCYTE; MAST CELL; NONHUMAN; PARASITOSIS; PIR-INTERNATIONAL PROTEIN SEQUENCE DATABASE; REVIEW; RNASE3 GENE; AMINO ACID SEQUENCE; ANIMAL; CELL GRANULE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MUCOSAL IMMUNITY; NUCLEOTIDE SEQUENCE; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BIOLOGICAL MARKERS; CYTOPLASMIC GRANULES; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; HOMEOSTASIS; HUMANS; IMMUNITY, MUCOSAL; INFLAMMATION; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; UP-REGULATION;

EID: 78651349308     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-10     Document Type: Review

References (161)

1. Ehrlich P. Uber die specifischen Granulation des Blutes. Archiv fur Anatomie und Physiologie, Physiologische Abteilung 1879,
2. Wardlaw AJ, Moqbel R, Kay AB. Eosinophils: biology and role in disease. Adv Immunol 1995, 60:151-266.
3. Kurashima K, Numata M, Yachie A, Sai Y, Ishizaka N, Fujimura M, Matsuda T, Ohkuma S. The role of vacuolar H(+)-ATPase in the control of intragranular pH and exocytosis in eosinophils. Lab Invest 1996, 75(5):689-698.
4. Neves JS, Weller PF. Functional extracellular eosinophil granules: novel implications in eosinophil immunobiology. Curr Opin Immunol 2009, 21(6):694-699.
5. Gleich GJ, Loegering DA, Maldonado JE. Identification of a major basic protein in guinea pig eosinophil granules. J Exp Med 1973, 137(6):1459-1471.
6. Peterson CG, Venge P. Purification and characterization of a new cationic protein--eosinophil protein-X (EPX)--from granules of human eosinophils. Immunology 1983, 50(1):19-26.
7. Desser RK, Himmelhoch SR, Evans WH, Januska M, Mage M, Shelton E. Guinea pig heterophil and eosinophil peroxidase. Arch Biochem Biophys 1972, 148(2):452-465.
8. Olsson I, Venge P, Spitznagel JK, Lehrer RI. Arginine-rich cationic proteins of human eosinophil granules: comparison of the constituents of eosinophilic and neutrophilic leukocytes. Lab Invest 1977, 36(5):493-500.
9. Iwasaki H, Mizuno S, Mayfield R, Shigematsu H, Arinobu Y, Seed B, Gurish MF, Takatsu K, Akashi K. Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med 2005, 201(12):1891-1897.
10. Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, Uike N, Niiro H, Takenaka K, Nagafuji K, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med 2009, 206(1):183-193.
11. Egesten A, Calafat J, Weller PF, Knol EF, Janssen H, Walz TM, Olsson I. Localization of granule proteins in human eosinophil bone marrow progenitors. Int Arch Allergy Immunol 1997, 114(2):130-138.
12. Gruart V, Truong MJ, Plumas J, Zandecki M, Kusnierz JP, Prin L, Vinatier D, Capron A, Capron M. Decreased expression of eosinophil peroxidase and major basic protein messenger RNAs during eosinophil maturation. Blood 1992, 79(10):2592-2597.
13. Carlson M, Oberg G, Peterson C, Venge P. Releasability of human hypereosinophilic eosinophils is related to the density of the cells. Br J Haematol 1994, 86(1):41-47.
14. Bystrom J, Tenno T, Hakansson L, Amin K, Trulson A, Hogbom E, Venge P. Monocytes, but not macrophages, produce the eosinophil cationic protein. Apmis 2001, 109(7-8):507-516.
15. Monteseirin J, Vega A, Chacon P, Camacho MJ, El Bekay R, Asturias JA, Martinez A, Guardia P, Perez-Cano R, Conde J. Neutrophils as a novel source of eosinophil cationic protein in IgE-mediated processes. J Immunol 2007, 179(4):2634-2641.
16. Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, Kephart GM, Wagner JM, George TJ, Gleich GJ, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998, 63(6):715-722.
17. Bystrom J, Garcia RC, Hakansson L, Karawajczyk M, Moberg L, Soukka J, Venge P. Eosinophil cationic protein is stored in, but not produced by, peripheral blood neutrophils. Clin Exp Allergy 2002, 32(7):1082-1091.
18. Handen JS, Rosenberg HF. Intronic enhancer activity of the eosinophil-derived neurotoxin (RNS2) and eosinophil cationic protein (RNS3) genes is mediated by an NFAT-1 consensus binding sequence. J Biol Chem 1997, 272(3):1665-1669.
19. Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M. Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet 1995, 10(2):219-223.
20. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 1986, 83(10):3146-3150.
21. Rosenberg HF. Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity. J Biol Chem 1995, 270(14):7876-7881.
22. Boix E, Leonidas DD, Nikolovski Z, Nogues MV, Cuchillo CM, Acharya KR. Crystal structure of eosinophil cationic protein at 2.4 A resolution. Biochemistry 1999, 38(51):16794-16801.
23. Sorrentino S, Glitz DG. Ribonuclease activity and substrate preference of human eosinophil cationic protein (ECP). FEBS Lett 1991, 288(1-2):23-26.
24. Rosenberg HF, Ackerman SJ, Tenen DG. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 1989, 170(1):163-176.
25. Eriksson J, Woschnagg C, Fernvik E, Venge P. A SELDI-TOF MS study of the genetic and post-translational molecular heterogeneity of eosinophil cationic protein. J Leukoc Biol 2007, 82(6):1491-1500.
26. Peterson CG, Jornvall H, Venge P. Purification and characterization of eosinophil cationic protein from normal human eosinophils. Eur J Haematol 1988, 40(5):415-423.
27. Pous J, Mallorqui-Fernandez G, Peracaula R, Terzyan SS, Futami J, Tada H, Yamada H, Seno M, de Llorens R, Gomis-Ruth FX, et al. Three-dimensional structure of human RNase 1 delta N7 at 1.9 A resolution. Acta Crystallogr D Biol Crystallogr 2001, 57(Pt 4):498-505.
28. Maeda T, Mahara K, Kitazoe M, Futami J, Takidani A, Kosaka M, Tada H, Seno M, Yamada H. RNase 3 (ECP) is an extraordinarily stable protein among human pancreatic-type RNases. J Biochem (Tokyo) 2002, 132(5):737-742.
29. Ulrich M, Petre A, Youhnovski N, Promm F, Schirle M, Schumm M, Pero RS, Doyle A, Checkel J, Kita H, et al. Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase. J Biol Chem 2008, 283(42):28629-28640.
30. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986, 321(6070):613-616.
31. Carreras E, Boix E, Rosenberg HF, Cuchillo CM, Nogues MV. Both aromatic and cationic residues contribute to the membrane-lytic and bactericidal activity of eosinophil cationic protein. Biochemistry 2003, 42(22):6636-6644.
32. Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, Nogues MV. Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Mol Cell Biochem 2005, 272(1-2):1-7.
33. Fredens K, Dahl R, Venge P. In vitro studies of the interaction between heparin and eosinophil cationic protein. Allergy 1991, 46(1):27-29.
34. Maeda T, Kitazoe M, Tada H, de Llorens R, Salomon DS, Ueda M, Yamada H, Seno M. Growth inhibition of mammalian cells by eosinophil cationic protein. Eur J Biochem 2002, 269(1):307-316.
35. Fan TC, Fang SL, Hwang CS, Hsu CY, Lu XA, Hung SC, Lin SC, Chang MD. Characterization of molecular interactions between eosinophil cationic protein and heparin. J Biol Chem 2008, 283(37):25468-25474.
36. Trulson A, Bystrom J, Engstrom A, Larsson R, Venge P. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy 2007, 37(2):208-218.
37. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, Michalek SM, Rosenberg HF, Zhang N, Oppenheim JJ. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008, 205(1):79-90.
38. Torrent M, Navarro S, Moussaoui M, Nogues MV, Boix E. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 2008, 47(11):3544-3555.
39. Torrent M, de la Torre BG, Nogues VM, Andreu D, Boix E. Bactericidal and membrane disruption activities of the eosinophil cationic protein are largely retained in an N-terminal fragment. Biochem J 2009, 421(3):425-434.
40. Jonsson UB, Bystrom J, Stalenheim G, Venge P. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy 2002, 32(7):1092-1095.
41. Rubin J, Zagai U, Blom K, Trulson A, Engstrom A, Venge P. The coding ECP 434(G > C) gene polymorphism determines the cytotoxicity of ECP but has minor effects on fibroblast-mediated gel contraction and no effect on RNase activity. J Immunol 2009, 183(1):445-451.
42. Koh GC, Shek LP, Goh DY, Van BH, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007, 101(4):696-705.
43. Bjork A, Venge P, Peterson CG. Measurements of ECP in serum and the impact of plasma coagulation. Allergy 2000, 55(5):442-448.
44. Peterson CG, Enander I, Nystrand J, Anderson AS, Nilsson L, Venge P. Radioimmunoassay of human eosinophil cationic protein (ECP) by an improved method. Establishment of normal levels in serum and turnover in vivo. Clin Exp Allergy 1991, 21(5):561-567.
45. Peterson CG, Venge P. Interaction and complex-formation between the eosinophil cationic protein and alpha 2-macroglobulin. Biochem J 1987, 245(3):781-787.
46. LaMarre J, Wollenberg GK, Gonias SL, Hayes MA. Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest 1991, 65(1):3-14.
47. Wardlaw AJ. Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm. J Allergy Clin Immunol 1999, 104(5):917-926.
48. Amin K, Rinne J, Haahtela T, Simola M, Peterson CG, Roomans GM, Malmberg H, Venge P, Seveus L. Inflammatory cell and epithelial characteristics of perennial allergic and nonallergic rhinitis with a symptom history of 1 to 3 years' duration. J Allergy Clin Immunol 2001, 107(2):249-257.
49. Amin K, Ludviksdottir D, Janson C, Nettelbladt O, Bjornsson E, Roomans GM, Boman G, Seveus L, Venge P. Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med 2000, 162(6):2295-2301.
50. Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M, McGovern TW, Gleich GJ. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998, 252(3):418-425.
51. Press MF, King WJ. Distribution of peroxidase and granulocytes in the human uterus. Lab Invest 1986, 54(2):188-203.
52. Gouon-Evans V, Lin EY, Pollard JW. Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development. Breast Cancer Res 2002, 4(4):155-164.
53. Leiferman KM, Peters MS, Gleich GJ. The eosinophil and cutaneous edema. J Am Acad Dermatol 1986, 15(3):513-517.
54. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999, 103(12):1719-1727.
55. Muller E. Localization of eosinophils in the thymus by the peroxidase reaction. Histochemistry 1977, 52(3):273-279.
56. Malm-Erjefalt M, Greiff L, Ankerst J, Andersson M, Wallengren J, Cardell LO, Rak S, Persson CG, Erjefalt JS. Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy 2005, 35(10):1334-1340.
57. Xu X, Hakansson L. Regulation of the release of eosinophil cationic protein by eosinophil adhesion. Clin Exp Allergy 2000, 30(6):794-806.
58. Kato Y, Fujisawa T, Terada A, Iguchi K, Kamiya H. Mechanisms of eosinophil cationic protein release in the serum: role of adhesion molecules. Int Arch Allergy Immunol 1999, 120(Suppl 1):60-64.
59. Takafuji S, Tadokoro K, Ito K, Nakagawa T. Release of granule proteins from human eosinophils stimulated with mast-cell mediators. Allergy 1998, 53(10):951-956.
60. Kita H, Weiler DA, Abu-Ghazaleh R, Sanderson CJ, Gleich GJ. Release of granule proteins from eosinophils cultured with IL-5. J Immunol 1992, 149(2):629-635.
61. Takafuji S, Tadokoro K, Ito K. Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. Allergy 1996, 51(8):563-568.
62. Woschnagg C, Rubin J, Venge P. Eosinophil cationic protein (ECP) is processed during secretion. J Immunol 2009, 183(6):3949-3954.
63. Shoji S, Kanazawa H, Hirata K, Kurihara N, Yoshikawa J. Clinical implication of protein levels of IL-5 in induced sputum in asthmatic patients. J Asthma 1998, 35(3):243-249.
64. Davis MD, Plager DA, George TJ, Weiss EA, Gleich GJ, Leiferman KM. Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol 2003, 112(5):988-994.
65. Lampinen M, Ronnblom A, Amin K, Kristjansson G, Rorsman F, Sangfelt P, Safsten B, Wagner M, Wanders A, Winqvist O, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut 2005, 54(12):1714-1720.
66. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009, 137(4):1238-1249.
67. Fujimoto K, Kubo K, Matsuzawa Y, Sekiguchi M. Eosinophil cationic protein levels in induced sputum correlate with the severity of bronchial asthma. Chest 1997, 112(5):1241-1247.
68. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, Seveus L, Trulson A. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999, 29(9):1172-1186.
69. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004, 53(12):1806-1812.
70. Bartoli ML, Bacci E, Carnevali S, Cianchetti S, Dente FL, Di Franco A, Giannini D, Taccola M, Vagaggini B, Paggiaro PL. Clinical assessment of asthma severity partially corresponds to sputum eosinophilic airway inflammation. Respir Med 2004, 98(2):184-193.
71. Koh YY, Kang H, Kim CK. Ratio of serum eosinophil cationic protein/blood eosinophil counts in children with asthma: comparison between acute exacerbation and clinical remission. Allergy Asthma Proc 2003, 24(4):269-274.
72. Tischendorf FW, Brattig NW, Lintzel M, Buttner DW, Burchard GD, Bork K, Muller M. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. Trop Med Int Health 2000, 5(12):898-905.
73. Ooi CY, Day AS, Jackson R, Bohane TD, Tobias V, Lemberg DA. Eosinophilic esophagitis in children with celiac disease. J Gastroenterol Hepatol 2008, 23(7 Pt 1):1144-1148.
74. Tischendorf FW, Brattig NW, Buttner DW, Pieper A, Lintzel M. Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. Acta Trop 1996, 62(3):171-182.
75. Kristjansson S, Bjarnarson SP, Wennergren G, Palsdottir AH, Arnadottir T, Haraldsson A, Jonsdottir I. Respiratory syncytial virus and other respiratory viruses during the first 3 months of life promote a local TH2-like response. J Allergy Clin Immunol 2005, 116(4):805-811.
76. Karawajczyk M, Pauksen K, Peterson CG, Eklund E, Venge P. The differential release of eosinophil granule proteins. Studies on patients with acute bacterial and viral infections. Clin Exp Allergy 1995, 25(8):713-719.
77. Niehaus MD, Gwaltney JM, Hendley JO, Newman MJ, Heymann PW, Rakes GP, Platts-Mills TA, Guerrant RL. Lactoferrin and eosinophilic cationic protein in nasal secretions of patients with experimental rhinovirus colds, natural colds, and presumed acute community-acquired bacterial sinusitis. J Clin Microbiol 2000, 38(8):3100-3102.
78. Ashitani J, Yanagi S, Arimura Y, Sano A, Mukae H. Acute respiratory distress syndrome induced by rifampicin with high levels of neutrophil and eosinophil products in bronchoalveolar lavage fluid. Respiration 2003, 70(5):541-543.
79. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989, 139(3):801-805.
80. Trautmann A, Schmid-Grendelmeier P, Kruger K, Crameri R, Akdis M, Akkaya A, Brocker EB, Blaser K, Akdis CA. T cells and eosinophils cooperate in the induction of bronchial epithelial cell apoptosis in asthma. J Allergy Clin Immunol 2002, 109(2):329-337.
81. Zagai U, Dadfar E, Lundahl J, Venge P, Skold CM. Eosinophil cationic protein stimulates TGF-beta1 release by human lung fibroblasts in vitro. Inflammation 2007, 30(5):153-160.
82. Kocak AK, Bor O, Yildiz B, Erdogan L, Us T. T-lymphocyte activation and the levels of eosinophilic cationic protein and interleukin-5 in asthmatic children with acute exacerbation and effect of glucocorticoid treatment. Allergy Asthma Proc 2006, 27(4):371-377.
83. Marcucci F, Sensi L, Di Cara G, Salvatori S, Bernini M, Pecora S, Burastero SE. Three-year follow-up of clinical and inflammation parameters in children monosensitized to mites undergoing sub-lingual immunotherapy. Pediatr Allergy Immunol 2005, 16(6):519-526.
84. Yamamoto H, Sedgwick JB, Vrtis RF, Busse WW. The effect of transendothelial migration on eosinophil function. Am J Respir Cell Mol Biol 2000, 23(3):379-388.
85. Shi HZ, Humbles A, Gerard C, Jin Z, Weller PF. Lymph node trafficking and antigen presentation by endobronchial eosinophils. J Clin Invest 2000, 105(7):945-953.
86. Peterson CG, Skoog V, Venge P. Human eosinophil cationic proteins (ECP and EPX) and their suppressive effects on lymphocyte proliferation. Immunobiology 1986, 171(1-2):1-13.
87. Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H. Inhibition of ongoing immunoglobulin production by eosinophil cationic protein. Clin Immunol Immunopathol 1992, 64(1):84-88.
88. Kimata H, Yoshida A, Ishioka C, Jiang Y, Mikawa H. Eosinophil cationic protein inhibits immunoglobulin production and proliferation in vitro in human plasma cells. Cell Immunol 1992, 141(2):422-432.
89. Sont JK, Han J, van Krieken JM, Evertse CE, Hooijer R, Willems LN, Sterk PJ. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996, 51(5):496-502.
90. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991, 87(4):1470-1473.
91. Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res 2009, 58(10):631-638.
92. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 1984, 133(4):2180-2185.
93. Okayama Y, el-Lati SG, Leiferman KM, Church MK. Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J Allergy Clin Immunol 1994, 93(5):900-909.
94. Patella V, de Crescenzo G, Marino I, Genovese A, Adt M, Gleich GJ, Marone G. Eosinophil granule proteins activate human heart mast cells. J Immunol 1996, 157(3):1219-1225.
95. Luster AD, Tager AM. T-cell trafficking in asthma: lipid mediators grease the way. Nat Rev Immunol 2004, 4(9):711-724.
96. Messmer EM, May CA, Stefani FH, Welge-Luessen U, Kampik A. Toxic eosinophil granule protein deposition in corneal ulcerations and scars associated with atopic keratoconjunctivitis. Am J Ophthalmol 2002, 134(6):816-821.
97. Hohlfeld JM, Schmiedl A, Erpenbeck VJ, Venge P, Krug N. Eosinophil cationic protein alters pulmonary surfactant structure and function in asthma. J Allergy Clin Immunol 2004, 113(3):496-502.
98. Trocme SD, Hallberg CK, Gill KS, Gleich GJ, Tyring SK, Brysk MM. Effects of eosinophil granule proteins on human corneal epithelial cell viability and morphology. Invest Ophthalmol Vis Sci 1997, 38(3):593-599.
99. Lundgren JD, Davey RT, Lundgren B, Mullol J, Marom Z, Logun C, Baraniuk J, Kaliner MA, Shelhamer JH. Eosinophil cationic protein stimulates and major basic protein inhibits airway mucus secretion. J Allergy Clin Immunol 1991, 87(3):689-698.
100. Altman LC, Ayars GH, Baker C, Luchtel DL. Cytokines and eosinophil-derived cationic proteins upregulate intercellular adhesion molecule-1 on human nasal epithelial cells. J Allergy Clin Immunol 1993, 92(4):527-536.
101. Chihara J, Yamamoto T, Kurachi D, Kakazu T, Higashimoto I, Nakajima S. Possible release of eosinophil granule proteins in response to signaling from intercellular adhesion molecule-1 and its ligands. Int Arch Allergy Immunol 1995, 108(Suppl 1):52-54.
102. Chihara J, Urayama O, Tsuda A, Kakazu T, Higashimoto I, Yamada H. Eosinophil cationic protein induces insulin-like growth factor I receptor expression on bronchial epithelial cells. Int Arch Allergy Immunol 1996, 111(Suppl 1):43-45.
103. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003, 125(6):1660-1669.
104. Dominguez-Ortega J, Perez-Bedmar J, Rodriguez-Jimenez B, Butron M, Kindelan C, Ledesma A. Eosinophilic esophagitis due to profilin allergy. J Investig Allergol Clin Immunol 2009, 19(4):338-339.
105. Minshall EM, Leung DY, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997, 17(3):326-333.
106. Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, McElwain K, McElwain S, Friedman S, Broide DH. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest 2004, 113(4):551-560.
107. Zagai U, Lundahl J, Klominek J, Venge P, Skold CM. Eosinophil cationic protein stimulates migration of human lung fibroblasts in vitro. Scand J Immunol 2009, 69(4):381-386.
108. Hernnas J, Sarnstrand B, Lindroth P, Peterson CG, Venge P, Malmstrom A. Eosinophil cationic protein alters proteoglycan metabolism in human lung fibroblast cultures. Eur J Cell Biol 1992, 59(2):352-363.
109. Solarewicz-Madejek K, Basinski TM, Crameri R, Akdis M, Akkaya A, Blaser K, Rabe KF, Akdis CA, Jutel M. T cells and eosinophils in bronchial smooth muscle cell death in asthma. Clin Exp Allergy 2009, 39(6):845-855.
110. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348(13):1201-1214.
111. Plotz SG, Abeck D, Seitzer U, Hein R, Ring J. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol 2000, 80(3):221.
112. Park YJ, Oh EJ, Park JW, Kim M, Han K. Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. Ann Clin Lab Sci 2006, 36(3):262-266.
113. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124(6):1319-1325. e1313..
114. Plager DA, Davis MD, Andrews AG, Coenen MJ, George TJ, Gleich GJ, Leiferman KM. Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol 2009, 183(6):4013-4020.
115. Yamada T, Shinohara K, Katsuki K. A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation. Am J Hematol 1998, 59(1):100-101.
116. Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol 2004, 113(1):50-58.
117. Venge P, Dahl R, Hallgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 1979, 14(4-5):641-649.
118. Sugihara R, Kumamoto T, Ito T, Ueyama H, Toyoshima I, Tsuda T. Human muscle protein degradation in vitro by eosinophil cationic protein (ECP). Muscle Nerve 2001, 24(12):1627-1634.
119. Tai PC, Ackerman SJ, Spry CJ, Dunnette S, Olsen EG, Gleich GJ. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1987, 1(8534):643-647.
120. Frickhofen N, Marker-Hermann E, Reiter A, Walz C, Jung B, Bauer H, Hochhaus A. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol 2004, 83(7):477-480.
121. Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol 1982, 70(5):361-366.
122. Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. J Clin Pathol 1981, 34(12):1343-1348.
123. Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 1997, 98(2):312-314.
124. Lose G, Frandsen B. Eosinophil cationic protein in urine in patients with urinary bladder tumors. Urol Res 1989, 17(5):295-297.
125. Navarro S, Aleu J, Jimenez M, Boix E, Cuchillo CM, Nogues MV. The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci 2008, 65(2):324-337.
126. Al-Owais MM, Hesse L, Talbot SJ, Adams DJ. Human non-pregnancy ribonuclease with anti-Kaposi's sarcoma activity. Cancer Lett 2002, 176(2):183-189.
127. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 2004, 113(1):30-37.
128. Kouriba B, Traore HA, Dabo A, Sangare L, Guindo H, Keita AS, Reimert CM, van Dam GJ, Deelder AM, Doumbo O, et al. Urinary disease in 2 Dogon populations with different exposure to Schistosoma haematobium infection: progression of bladder and kidney diseases in children and adults. J Infect Dis 2005, 192(12):2152-2159.
129. Gutierrez-Pena EJ, Knab J, Buttner DW. Immunoelectron microscopic evidence for release of eosinophil granule matrix protein onto microfilariae of Onchocerca volvulus in the skin after exposure to amocarzine. Parasitol Res 1998, 84(8):607-615.
130. Wildenburg G, Darge K, Knab J, Tischendorf FW, Bonow I, Buttner DW. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol 1994, 45(2):87-96.
131. McLaren DJ, Peterson CG, Venge P. Schistosoma mansoni: further studies of the interaction between schistosomula and granulocyte-derived cationic proteins in vitro. Parasitology 1984, 88(Pt 3):491-503.
132. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol 1990, 144(8):3166-3173.
133. Molina HA, Kierszenbaum F, Hamann KJ, Gleich GJ. Toxic effects produced or mediated by human eosinophil granule components on Trypanosoma cruzi. Am J Trop Med Hyg 1988, 38(2):327-334.
134. Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, Schmid I, Straumann A, Reichenbach J, Gleich GJ, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008, 14(9):949-953.
135. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 1989, 142(12):4428-4434.
136. Grunberg K, Smits HH, Timmers MC, de Klerk EP, Dolhain RJ, Dick EC, Hiemstra PS, Sterk PJ. Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am J Respir Crit Care Med 1997, 156(2 Pt 1):609-616.
137. Garofalo R, Kimpen JL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992, 120(1):28-32.
138. Dyer KD, Percopo CM, Fischer ER, Gabryszewski SJ, Rosenberg HF. Pneumoviruses infect eosinophils and elicit MyD88-dependent release of chemoattractant cytokines and interleukin-6. Blood 2009, 114(13):2649-2656.
139. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 1998, 26(14):3358-3363.
140. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998, 177(6):1458-1464.
141. Zhang J, Rosenberg HF. Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics 2000, 156(4):1949-1958.
142. Noguchi E, Iwama A, Takeda K, Takeda T, Kamioka M, Ichikawa K, Akiba T, Arinami T, Shibasaki M. The promoter polymorphism in the eosinophil cationic protein gene and its influence on the serum eosinophil cationic protein level. Am J Respir Crit Care Med 2003, 167(2):180-184.
143. Jonsson UB, Bystrom J, Stalenheim G, Venge P. A (G- > C) transversion in the 3' UTR of the human ECP (eosinophil cationic protein) gene correlates to the cellular content of ECP. J Leukoc Biol 2006, 79(4):846-851.
144. Munthe-Kaas MC, Gerritsen J, Carlsen KH, Undlien D, Egeland T, Skinningsrud B, Torres T, Carlsen KL. Eosinophil cationic protein (ECP) polymorphisms and association with asthma, s-ECP levels and related phenotypes. Allergy 2007, 62(4):429-436.
145. Kang I, An XH, Oh YK, Lee SH, Jung HM, Chae SC, Lee JH. Identification of polymorphisms in the RNase3 gene and the association with allergic rhinitis. Eur Arch Otorhinolaryngol 2010, 267(3):391-395.
146. Pereira MC, Oliveira DT, Olivieri EH, Rogatto SR, Carvalho AL, Landman G, Kowalski LP. The 434(G > C) polymorphism in the eosinophil cationic protein gene and its association with tissue eosinophilia in oral squamous cell carcinomas. J Oral Pathol Med 2010, 39(1):56-62.
147. Kim YJ, Kumaraswami V, Choi E, Mu J, Follmann DA, Zimmerman P, Nutman TB. Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. Am J Trop Med Hyg 2005, 73(1):125-130.
148. Eriksson J, Reimert CM, Kabatereine NB, Kazibwe F, Ireri E, Kadzo H, Eltahir HB, Mohamed AO, Vennervald BJ, Venge P. The 434(G > C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol 2007, 37(12):1359-1366.
149. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995, 182(1):219-231.
150. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356(9248):2144-2148.
151. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009, 360(10):985-993.
152. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009, 360(10):973-984.
153. Tarodo de la Fuente P, Romagnoli M, Carlsson L, Godard P, Bousquet J, Chanez P. Eosinophilic inflammation assessed by induced sputum in corticosteroid-dependent asthma. Respir Med 1999, 93(3):183-189.
154. Yamada T, Tani Y, Nakanishi H, Taguchi R, Arita M, Arai H. Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J
155. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007, 21(2):325-332.
156. Reimert CM, Fitzsimmons CM, Joseph S, Mwatha JK, Jones FM, Kimani G, Hoffmann KF, Booth M, Kabatereine NB, Dunne DW, et al. Eosinophil activity in Schistosoma mansoni infections in vivo and in vitro in relation to plasma cytokine profile pre- and posttreatment with praziquantel. Clin Vaccine Immunol 2006, 13(5):584-593.
157. Brightling CE, Ward R, Woltmann G, Bradding P, Sheller JR, Dworski R, Pavord ID. Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med 2000, 162(3 Pt 1):878-882.
158. Klimek L, Rasp G. Norm values for eosinophil cationic protein in nasal secretions: influence of specimen collection. Clin Exp Allergy 1999, 29(3):367-374.
159. Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP, LaMicela M, D'Amico L, Crimi N. Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 2001, 108(5):703-708.
160. Bonini S, Magrini L, Rotiroti G, Lambiase A, Tomassini M, Rumi C. The eosinophil and the eye. Allergy 1997, 52(34 Suppl):44-47.
161. Montan PG, van Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br J Ophthalmol 1996, 80(6):556-560.